Fosun Pharmaceuticals subsidiary prostate cancer drug bikaluamine tablets reviewed

Bicaruamine tablets are mainly used in the treatment of advanced prostate cancerIn FY2019, the first ® sales in China (excluding Hong Kong, Macao and Taiwan, the same below) were approximately RMB140 millionas of the date of this announcement, the Bicaruamine tablets listed in China mainly include AstraZeneca Pharmaceutical co., Ltd.'s Constand ®, Shanxi Zhendong Pharmaceutical Co., Ltd.'s Yan Leishu ®, and the Hajj ® of Shanghai's HajjAccording to the latest data of IQVIACHPA (provided by IQVIA, IQVIA is the world's leading professional information and strategic consulting service provider for the pharmaceutical and health industry; IQVIACHPA data represents the market for the sale of hospital selling drugs with more than 100 beds in China, and different drugs may differ from the respective sales channel layout, the actual sales situation may differ from the IQVIACHPA data in 2019, the sales of the Bicaru tablets in China are approximately RMB1.23 billionAs of April 2020, The total investment in research and development of the drug at this stage is approximately RMB13.69 million (unaudited) for the consistency evaluation of the drug.